Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | CLK2 | P49760 | 1/20 | 0.44 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.43 |
| ▸ | IKBKB | O14920 | 2/20 | 0.43 |
| ▸ | KDR | P35968 | 6/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.43 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.40 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.40 |
| ▸ | DDX3X | O00571 | 1/20 | 0.40 |
| ▸ | PTGES | O14684 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4343501 | 0.86 | PTPN11 (0.58) | MAPTFFAR1PTPN11IKBKBKDR | |
| SCHEMBL3837869 | 0.84 | GRM5 (0.47) | MAPTFFAR1PTPN11KDRPDGFRB | |
| SCHEMBL13623057 | 0.82 | NAMPT (0.43) | MAPTFFAR1CLK2IKBKBKDR | |
| SCHEMBL3836707 | 0.81 | PTPN1 (0.57) | MAPTFFAR1KDRPTGESGRM5 | |
| SCHEMBL14906245 | 0.79 | KDM4E (0.51) | MAPTFFAR1IKBKBKDRPDGFRB | |
| SCHEMBL4638868 | 0.79 | RET (0.41) | MAPTKDRPDGFRB | |
| SCHEMBL13669928 | 0.77 | CLK2 (0.38) | MAPTFFAR1CLK2IKBKBKDR | |
| SCHEMBL1024930 | 0.76 | FFAR1 (0.43) | FFAR1PTPN11IKBKBKDRPDGFRB | |
| SCHEMBL18339403 | 0.76 | IKBKB (0.46) | MAPTFFAR1IKBKBKDRPDGFRB | |
| SCHEMBL1026072 | 0.75 | FFAR1 (0.47) | FFAR1PTPN11IKBKBCSNK2A2CSNK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871753-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| EP-2274288-A2 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | Incyte Corporation (US) | 2011-01-19 | — | — | EP | disclosed |
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
| WO-2009132202-A2 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | MAPT 3239/4885FFAR1 1611/4885CLK2 1097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.